Drugs /

177lu-dotatoc

Back to Drugs List

Overview

NCI Definition [1]:
A radioconjugate consisting of the somatostatin analogue edotreotide labeled with lutetium Lu 177 with potential antineoplastic activities. Lutetium Lu 177-edotreotide binds to somatostatin receptors (SSTRs), with high affinity to type 2 SSTR, present on the cell membranes of many types of neuroendocrine tumor cells. Upon binding and internalization, this radioconjugate specifically delivers a cytotoxic dose of beta radiation to SSTR-positive cells. Edotreotide is produced by substituting tyrosine for phenylalanine at the 3 position of the somatostatin analogue octreotide (Tyr3-octreotide or TOC) and chelated by the bifunctional, macrocyclic chelating agent dodecanetetraacetic acid (DOTA).

Clinical Trials

View Clinical Trials for 177lu-dotatoc

177lu-dotatoc has been investigated in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial investigating 177lu-dotatoc, 1 is phase 2 (1 open).

SSTR1 Expression, SSTR2 Expression, and SSTR3 Expression are the most frequent biomarker inclusion criteria for 177lu-dotatoc clinical trials.

Adrenal gland pheochromocytoma, lung neuroendocrine neoplasm, and neuroendocrine carcinoma of unknown primary are the most common diseases being investigated in 177lu-dotatoc clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating 177lu-Dotatoc
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating 177lu-dotatoc and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
177lu-edotreotide, 177ludota]-toc, edotreotide lutetium lu-177, lutetium 177lu-edotreotide, lutetium lu 177 dota-tyr3-octreotide, lutetium lu 177-edotreotide
Drug Target(s) [2]:
SSTR1, SSTR2, SSTR3, SSTR4, SSTR5
NCIT ID [1]:
C88277

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.